Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Companies Planning UK Investment Cuts Over Repayments Predicted for 2023

Executive Summary

Many pharma firms are considering cutting their investment in clinical trials or reducing their supply to the UK market next year, a survey by industry group EMIG found.

You may also be interested in...

More Execs Speak Out Over Risks Of UK Voluntary Pricing Scheme For Life Sciences

In 2022, a total of five companies chose to exit the UK’s voluntary scheme that manages branded medicines spending. The departure of two big firms – AbbVie and Lilly – is seen as a deliberate tactic to send a clear signal to government that the scheme is not working for industry and is jeopardizing investment and access to medicines in the UK.

UK Industry Calls For 'Early & Open' Talks Over ‘Extreme’ 2023 Clawbacks

The current UK approach to drug pricing and access is "broken," and early talks with the government next year will be necessary to set out a "completely new future settlement," the pharmaceutical industry has warned. By contrast, the government claims that the pricing scheme is working as intended.

UK Pricing Scheme Negotiations Should Include Broader Representation

Generics and biosimilars manufacturers and patients should have greater influence on UK pricing scheme negotiations.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts